论文部分内容阅读
目的探讨依达拉奉联合疏血通治疗急性脑梗死患者的临床效果和安全性。方法将上区蔡县人民医院自2013年1月至2014年6月收治的124例急性脑梗死患者按照随机、自愿的原则分为对照组和观察组,每组各62例。对照组患者在常规治疗基础上加用疏血通注射液,观察组患者在对照组治疗基础上联合应用依达拉奉注射液,疗程均为2周。比较两组患者治疗后的临床效果和不良反应发生情况。结果治疗2周后观察组总有效率明显高于对照组,差异有统计学意义(95.2%vs 77.4%,P<0.05)。两组患者治疗期间均未发生严重不良反应,不良反应发生率差异无统计学意义。结论依达拉奉联合疏血通治疗急性脑梗死患者的临床效果,安全性好,值得在临床推广应用。
Objective To investigate the clinical effect and safety of edaravone combined with Shuxuetong in the treatment of patients with acute cerebral infarction. Methods One hundred and twenty-four patients with acute cerebral infarction who were treated in Caixian People’s Hospital of Shang District from January 2013 to June 2014 were divided into control group and observation group according to the principle of randomization and voluntariness, with 62 cases in each group. Patients in the control group were treated with Shuxuetong injection on the basis of routine treatment. Patients in the observation group were treated with edaravone in combination with the control group for 2 weeks. The clinical effects and adverse reactions of the two groups after treatment were compared. Results After 2 weeks of treatment, the total effective rate of the observation group was significantly higher than that of the control group (95.2% vs 77.4%, P <0.05). No serious adverse reactions occurred in the two groups during treatment, and there was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Edaravone combined with Shuxuetong in the treatment of patients with acute cerebral infarction clinical efficacy, safety, it is worth in the clinical application.